BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 22315118)

  • 1. Severe bronchorrhea in a patient with bronchioloalveolar carcinoma.
    Popat N; Raghavan N; McIvor RA
    Chest; 2012 Feb; 141(2):513-514. PubMed ID: 22315118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prompt control of bronchorrhea in patients with bronchioloalveolar carcinoma treated with gefitinib (Iressa).
    Milton DT; Kris MG; Gomez JE; Feinstein MB
    Support Care Cancer; 2005 Jan; 13(1):70-2. PubMed ID: 15558327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [EGFR tyrosine kinase inhibitors as a targeted therapy for bronchioloalveolar carcinoma of the lung: a case report of a clinically prompt and intensive response and literature review].
    Svoboda M; Fabian P; Slabý O; Stanková M; Lakomý R; Nemecek R; Vyzula R
    Klin Onkol; 2010; 23(4):224-30. PubMed ID: 20806820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A report of two bronchioloalveolar carcinoma cases which were rapidly improved by treatment with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 ("Iressa").
    Yano S; Kanematsu T; Miki T; Aono Y; Azuma M; Yamamoto A; Uehara H; Sone S
    Cancer Sci; 2003 May; 94(5):453-8. PubMed ID: 12824893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel effects of gefitinib on mucin production in bronchioloalveolar carcinoma; two case reports.
    Kitazaki T; Fukuda M; Soda H; Kohno S
    Lung Cancer; 2005 Jul; 49(1):125-8. PubMed ID: 15949598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erlotinib or gefitinib as first-choice therapy for bronchorrhea in bronchioloalveolar carcinoma.
    Sanz Rubiales A; de la Cruz V; Berezo JÁ; Torres MÁ
    J Pain Symptom Manage; 2014 Jun; 47(6):e7-9. PubMed ID: 24747679
    [No Abstract]   [Full Text] [Related]  

  • 7. Bronchioloalveolar carcinoma: not as easy as "BAC".
    West HL; Garfield DH
    J Thorac Oncol; 2009 Sep; 4(9):1047-8. PubMed ID: 19704334
    [No Abstract]   [Full Text] [Related]  

  • 8. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.
    Miller VA; Riely GJ; Zakowski MF; Li AR; Patel JD; Heelan RT; Kris MG; Sandler AB; Carbone DP; Tsao A; Herbst RS; Heller G; Ladanyi M; Pao W; Johnson DH
    J Clin Oncol; 2008 Mar; 26(9):1472-8. PubMed ID: 18349398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of refractory bronchorrhea by inhaled indomethacin in two patients with bronchioloalveolar carcinoma.
    Homma S; Kawabata M; Kishi K; Tsuboi E; Narui K; Nakatani T; Nakata K
    Chest; 1999 May; 115(5):1465-8. PubMed ID: 10334175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib.
    Wislez M; Antoine M; Baudrin L; Poulot V; Neuville A; Pradere M; Longchampt E; Isaac-Sibille S; Lebitasy MP; Cadranel J
    Lung Cancer; 2010 May; 68(2):185-91. PubMed ID: 19581016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A case of suspected lung metastasis of pancreatic carcinoma with bronchorrhea similar to bronchioloalveolar carcinoma].
    Mito K; Yamakami Y; Kashima K; Mizunoe S; Tokimatsu I; Ichimiya T; Hiramatsu K; Nagai H; Kadota J; Nasu M
    Nihon Kokyuki Gakkai Zasshi; 2002 Aug; 40(8):666-70. PubMed ID: 12428395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A case of bronchioloalveolar carcinoma successfully treated with low-dose, alternate-day administration of erlotinib].
    Yuyama K; Matsushita H; Egawa K; Osawa T; Tsubouchi Y; Takahashi T; Miura H
    Gan To Kagaku Ryoho; 2012 Mar; 39(3):433-5. PubMed ID: 22421774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma.
    Hata A; Katakami N; Fujita S; Kaji R; Imai Y; Takahashi Y; Nishimura T; Tomii K; Ishihara K
    J Thorac Oncol; 2010 Aug; 5(8):1197-200. PubMed ID: 20661086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to gefitinib in bronchioloalveolar carcinoma in the absence of EGFR mutation.
    Taja-Chayeb L; Candelaria M; Brom R; Trejo-Becerril C; Meza F; Duenas-Gonzalez A
    Lung Cancer; 2005 Nov; 50(2):259-63. PubMed ID: 16009451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IFCT-0401 Trial: a phase II study of gefitinib administered as first-line treatment in advanced adenocarcinoma with bronchioloalveolar carcinoma subtype.
    Cadranel J; Quoix E; Baudrin L; Mourlanette P; Moro-Sibilot D; Morere JF; Souquet PJ; Soria JC; Morin F; Milleron B;
    J Thorac Oncol; 2009 Sep; 4(9):1126-35. PubMed ID: 19574932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Gefitinib for advanced bronchioloalveolar carcinoma].
    Zhang XT; Wang SL; Li LY
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Jun; 26(3):340-3. PubMed ID: 15266843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.
    Hirsch FR; Varella-Garcia M; McCoy J; West H; Xavier AC; Gumerlock P; Bunn PA; Franklin WA; Crowley J; Gandara DR;
    J Clin Oncol; 2005 Oct; 23(28):6838-45. PubMed ID: 15998906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged remission of disseminated atypical adenomatous hyperplasia under gefitinib.
    Pastorino U; Calabrò E; Tamborini E; Marchianò A; Orsenigo M; Fabbri A; Sozzi G; Novello S; De Marinis F
    J Thorac Oncol; 2009 Feb; 4(2):266-7. PubMed ID: 19179908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of multifocal bronchioloalveolar cell carcinoma with ZD1839 (Iressa) in two patients.
    Chang GC; Yang TY; Wang NS; Huang CM; Chiang CD
    J Formos Med Assoc; 2003 Jun; 102(6):407-11. PubMed ID: 12923594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.